Global Oncology Based In-vivo CRO Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Indication;

Blood Cancer & Solid Tumors - Syngeneic Model, Patient-Derived Xenograft (PDX), & Xenograft, and Other.

By Model;

Syngeneic, Xenograft, and Patient Derived Xenograft (PDX).

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn154480927 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Oncology Based In-vivo CRO Market (USD Million), 2021 - 2031

In the year 2024, the Global Oncology Based In-vivo CRO Market was valued at USD 995.19 million. The size of this market is expected to increase to USD 1,651.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.

The global oncology-based in-vivo Contract Research Organization (CRO) market is experiencing significant growth, driven by the escalating burden of cancer worldwide. With cancer remaining one of the leading causes of morbidity and mortality, the need for innovative and effective treatments is paramount. In-vivo CROs play a crucial role in this context by providing comprehensive services for preclinical and clinical research, enabling pharmaceutical and biotechnology companies to accelerate the development of new cancer therapies. These organizations offer specialized expertise and infrastructure, which are essential for conducting complex in-vivo studies that form the backbone of oncology research.

Technological advancements have been a major catalyst in the growth of the in-vivo CRO market. Innovations in imaging techniques, genomics, and biomarker identification have significantly enhanced the precision and efficiency of in-vivo studies. These advancements not only improve the accuracy of cancer research but also reduce the time and cost associated with drug development. As a result, pharmaceutical companies are increasingly outsourcing their in-vivo research needs to CROs, leveraging their state-of-the-art technologies and specialized skills to gain a competitive edge in the oncology market.

Despite the promising growth prospects, the market faces several challenges that could impede its expansion. The high cost of conducting in-vivo studies, coupled with ethical concerns surrounding animal testing, presents significant hurdles. Additionally, stringent regulatory requirements and the complexity of obtaining approvals for in-vivo studies can slow down the research process. Moreover, the limited availability of skilled personnel capable of conducting sophisticated in-vivo studies further restricts market growth. Addressing these challenges is crucial for the sustained expansion of the oncology-based in-vivo CRO market.

Opportunities for growth in this market are abundant, particularly in emerging markets where healthcare infrastructure is rapidly developing. Increased collaborations and partnerships between pharmaceutical companies, academic institutions, and CROs can drive innovation and efficiency in research. The integration of advanced technologies such as artificial intelligence and big data analytics holds the potential to revolutionize in-vivo studies by providing deeper insights and accelerating the research process. Furthermore, ongoing government initiatives and funding dedicated to cancer research can provide additional support, fostering an environment conducive to the growth of oncology-based in-vivo CROs.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Model
    3. Market Snapshot, By Region
  4. Global Oncology Based In-vivo CRO Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Pharmaceutical R&D Investment
        2. Regulatory Support and Approvals
        3. Growth in Personalized Medicine
      2. Restraints
        1. Regulatory Hurdles
        2. Limited Availability of Skilled Personnel
        3. Variability in Animal Models
      3. Opportunities
        1. Technological Integration
        2. Development of Novel Therapeutics
        3. Government Initiatives and Funding
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Oncology Based In-vivo CRO Market, By Indication, 2021- 2031(USD Million)
      1. Blood cancer
      2. Solid tumors
      3. Syngeneic model
      4. Patient-Derived Xenograft (PDX)
      5. Xenograft
      6. Other
    2. Global Oncology Based In-vivo CRO Market, By Model, 2021- 2031(USD Million)
      1. Syngeneic
      2. Xenograft
      3. Patient Derived Xenograft (PDX)
    3. Global Oncology Based In-vivo CRO Market, By Geography, 2021- 2031(USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Charles River Laboratory (CRL)
      2. ICON Plc
      3. Covance
      4. Eurofins Scientific
      5. Taconic Biosciences
      6. Crown Bioscience
      7. Toxikon, Inc.
      8. WuXi AppTec
      9. EVOTEC
      10. The Jackson Laboratory
  7. Analyst Views
  8. Future Outlook of the Market